QUOTE AND NEWS
FiercePharma  Sep 17  Comment 
MannKind has been starved for cash, so it was huge for the California-based pharma to strike a deal with Big Pharma player Sanofi to help market its inhaled insulin Afrezza. But Sanofi has something else that can cut their costs and fatten up...
SeekingAlpha  Sep 16  Comment 
By The Behavioral Economist: As investors, many of us subscribe to the belief that "the devil is in the details." That is to say, we examine every link in the chain, we search for every chip in the armor, and we profess disproportionate value to...
SeekingAlpha  Sep 16  Comment 
By Psycho Analyst: "Diabetes in Control," a newsletter directed at diabetes professionals, just published a long, technical interview with Al Mann, MannKind's (NASDAQ:MNKD) founder, which answers many questions that have been raised by investors...
SeekingAlpha  Sep 12  Comment 
By Trevor Lowenthal: MannKind (NASDAQ:MNKD) is a commercial stage biopharmacetuical company focusing on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. Background...
SeekingAlpha  Sep 11  Comment 
By Psycho Analyst: More Details about the Sanofi/MannKind Deal Emerge from the Morgan Stanley Global Healthcare Conference. MannKind (NASDAQ:MNKD) management presented Tuesday at the Morgan Stanley Global Healthcare Conference. The analysts...
SeekingAlpha  Sep 9  Comment 
By SA Transcripts: MannKind Corp. (NASDAQ:MNKD) Morgan Stanley Global Healthcare Conference Transcript September 9, 2014 12:55 PM ET Executives Matthew Pfeffer - Corporate Vice President and CFO Hakan Edstrom - President and COO ...
Motley Fool  Sep 9  Comment 
MannKind's stock has handily outperformed the S&P 500 in 2014. Find out what's sent its shares higher and whether or not it has more room to run.
Benzinga  Aug 27  Comment 
Analysts at Jefferies initiated coverage on MannKind (NASDAQ: MNKD) with a Buy rating. The target price for MannKind is set to $10. MannKind shares have jumped 23.99% over the past 52 weeks, while the S&P 500 index has gained 22.66% in the...
SeekingAlpha  Aug 26  Comment 
By Orange Peel Investments: By Parke Shall We think that MannKind (NASDAQ:MNKD) is eventually going to be a long term winner for those holding the stock. Though we rarely get involved with the biotech sector, we've been following the MannKind...
SeekingAlpha  Aug 25  Comment 
By Achilles Research: MannKind's (NASDAQ:MNKD) stock has been in freefall since the end of June and the decline in share price was quite deserved. In fact, I can hardly imagine any other biopharmaceutical company that is as loved as MannKind, even...




 

MannKind is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for diabetes, cancer, and inflammatory and autoimmune diseases. The company's lead product, the Technosphere Insulin System, meant for the treatment of diabetes, is in a series of pivotal phase III trial in the U.S. This product utilizes MannKind s proprietary dry powder Technosphere formulation of insulin. It is inhaled deep into the lungs using the company s MedTone inhaler. Besides the company s development of Technosphere, MannKind is pursuing efforts aimed at the discovery and development of novel drugs for metabolic and immunological diseases. The company also has early-stage development programs for the treatment of solid-tumor cancers. MannKind initiated phase I trials with its cancer candidates in early 2007. MannKind's corporate headquarters and immunology research operations are located in Valencia, CA. Significant operations, including the Technosphere Insulin research, development and manufacturing are located in Danbury, CT. The company's initial public offering (IPO) took place in late July 2004.

Business & Financial Metrics[1]

In 2009, MannKind incurred a net loss of $220.1 million and reported no revenue. This represents a 27.4% reduction in net loss from 2008, when the company lost $303.0 million. Since its inception in 1991, MannKind has lost $1.60 billion and generated $3.0 million in revenues.

Competition

MannKind's primary competitors include:

References

  1. MNKD 2009 10-K pg. 64  
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki